27.3 C
Vientiane
Tuesday, September 9, 2025
spot_img
Home Blog Page 350

NX Taiwan Awarded Healthy Workplace Certification by “Ministry of Health and Welfare”

– Received High Praise for Promoting Health Management and Contributing to Local Communities –

TOKYO, Aug. 4, 2025 /PRNewswire/ — Nippon Express (Taiwan) Co., Ltd. (hereinafter “NX Taiwan”), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by the Health Promotion Administration (HPA) of “Taiwan’s Ministry of Health and Welfare” in recognition of the company’s commitment to creating sustainable workplaces that emphasize the health and welfare of employees.

Logo: 
https://drive.google.com/file/d/1dqm0cxpYamnvMUra1AGXMuGlX932Z353/view?usp=drive_link

Employees and certificate (center: Chairman Masaru Kawamoto): 
https://drive.google.com/file/d/1sCkSZjqTtFmBltlXoiFEee_6XvioSXT7/view?usp=sharing 

“Walkii Day” results presentation: 
https://drive.google.com/file/d/1mwxtlrKubLR2kd_vWXRWY4faN8MHP1ga/view?usp=sharing

The Healthy Workplace Certification is an official certification system established by the HPA to encourage companies to pursue health management. Firms are evaluated on their comprehensive health management efforts, including the physical and mental health and well-being of their employees, and their contributions to the community, based on four aspects of the World Health Organization’s healthy workplace framework and model: the physical work environment, the psychosocial work environment, personal health resources in the workplace and enterprise community involvement.

Based on the concept of “valuing people,” NX Taiwan has been actively promoting employees’ health and creating safe and comfortable work environments by acquiring ISO 45001:2018 (occupational health and safety management system) certification and enhancing its employee welfare programs, and HPA’s appreciation of these multifaceted health management measures led to the company’s most recent certification. Among the specific initiatives being implemented are:

– Introduction of an Employee Assistance Program (EAP)
NX Taiwan has established a 24-hour consultation service offering a variety of support, including psychological counseling, stress management courses, and legal, medical, and financial consultations.

– Enhancement of health checkups and preventive services
Health checkups, cancer screenings, and preconception checkups (pre-marital examinations) are being provided in accordance with employees’ age, sex, and life stage. NX Taiwan has developed an support system that exceeds statutory standards, while striving to detect and prevent diseases early on.

– Promotion of “Green Walking” activities
NX Taiwan encourages employees to walk on a daily basis using a dedicated app, achieving a participation rate of 53% for a total of 233 million steps in 2025.

– Hosting of diverse health promotion and exchange events
NX Taiwan provides health lectures, physical fitness tests, sports club activities (badminton, dragon boat racing, etc.), weight loss programs and healthy food information. The results of using the health promotion app “Walkii” presented on “Walkii Day” were shared with more than 40 companies and acclaimed by the “Ministry of Health and Welfare” and the “Taiwan Institute of Sports Science.”

– Access to wide-ranging benefits
NX Taiwan helps improve the quality of life of employees and their families by offering company trips and event subsidies as well as health checkups and travel aid that encompass family members, and by engaging in CSR activities (tree planting, cleanups, blood drives, etc.).

The NX Group will continue striving to realize safe and healthy work environments and promote sustainability, aiming to improve its employees’ quality of life and achieve sustainable corporate growth.

About the NX Group:
https://drive.google.com/file/d/1mbvBL6C8THZNrR5LREgGeafNkEdaAmV-/view?usp=drive_link

NX Group official website: https://www.nipponexpress.com/
NX Group’s official LinkedIn account: https://www.linkedin.com/company/nippon-express-group/

The Westin Singapore Launches Exclusive “Move Well Marathon Package” for SCSM 2025 Participants

SINGAPORE, Aug. 4, 2025 /PRNewswire/ — In celebration of its third consecutive year as the Official Elite Hotel of the Standard Chartered Singapore Marathon (SCSM), The Westin Singapore is proud to present its new “Move Well: Marathon Package“, thoughtfully crafted to help runners recharge and recover in luxury and comfort.

Deluxe Room at The Westin Singapore
Deluxe Room at The Westin Singapore

Available for stays from 4 to 8 December 2025, the package is designed to support runners’ performance and well-being before and after the race. Guests who book this exclusive offer will enjoy:

Located in the heart of the Central Business District (CBD) and Marina Bay, with direct MRT access and scenic running routes around Marina Bay and Gardens by the Bay, The Westin Singapore is a haven for runners who value comfort, performance, and holistic well-being. Conveniently situated near the flag-off venue, guests can enjoy a scenic walk along the Marina Bay promenade while avoiding road closure congestion.

This offer aligns with the brand’s Move Well pillar and commitment to helping guests stay balanced and energized while traveling.

To further commemorate this milestone, The Westin Singapore is proud to partner with the Singapore Disability Sports Council (SDSC) as its official beneficiary, raising funds in support of para-athletes across all sporting disciplines. Guests who wish to contribute can do so by purchasing our exclusive charity shirts through our e-shop.

Book your stay now and give yourself the space to run, recover, and rise:
https://www.marriott.com/offers/move-well-marathon-package-off-165111/sinwi-the-westin-singapore

– end –

About The Westin Singapore

As Singapore’s first integrated hotel located within an office building, The Westin Singapore occupies levels 32 to 46 of Asia Square Tower 2 commercial development in Marina Bay, the heart of Singapore’s bustling financial district. The hotel offers 305 guestrooms and suites, four distinct dining venues, an outdoor infinity pool with a stunning view over Singapore’s south coast, the Heavenly Spa by Westin™, WestinWORKOUT® fitness studio equipped with state-of-the-art Technogym and TRX fitness equipment and 1,350 square meters of versatile event spaces, all designed with guests’ well-being in mind.

For more information, please visit thewestinsingapore.com.

About Westin® Hotels & Resorts 

Westin Hotels & Resorts, hospitality’s global leader in well-being for more than a decade, empowers guests to transcend the rigors of travel while on the road through the brand’s Six Pillars of well-being: Sleep Well, Eat Well, Move Well, Feel Well, Work Well, and Play Well. At more than 240 hotels and resorts in over 40 countries and territories, guests can benefit from distinct wellness experiences including the brand’s iconic and award-winning Heavenly® Bed, signature WestinWORKOUT® offerings such as its 24/7 Fitness Studios, WestinWORKOUT Routes, and its versatile Gear Lending program featuring the latest in recovery and strength training from Hyperice and Bala, delicious and nutritious menu offerings on their Eat Well menu, and more. For more information, please visit www.westin.com and stay connected on X, Instagram, TikTok, and Facebook. Westin is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com.

About Marriott International

Marriott International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of nearly 9,100 properties across more than 30 leading brands in 142 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts all around the world. The company offers Marriott Bonvoy®, its highly awarded travel program.  For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com.  In addition, connect with us on Facebook and @MarriottIntl on X and Instagram.

Media Contact:

Margareth Sugiarto

Assistant Director, Marketing Communications

The Westin Singapore

65.6922.6864

Margareth.Sugiarto@westin.com  

Teo Shi Min

Marketing Communications Manager

The Westin Singapore

65.6922.6861

Shimin.Teo@westin.com  

 

 

 

Muan Specialty, CREATIVE TALK Host Laos’s First Marketing Conference

Muan Specialty, CREATIVE TALK Host Laos’s First Marketing Conference
(photo supplied)

Muan Specialty, in collaboration with CREATIVE TALK, organized the CTC LAOS MARKETING 2025 conference and workshop at the Holiday Inn & Suites Vientiane from 26 to 27 July.

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC).

This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan and Australia. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024.

ABT-301 is an oral HDAC1/2/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting “cold tumors” into “hot tumors” to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs.

Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors—further supporting its suitability for use in combination immunotherapy.

Approximately 95% of mCRC patients are pMMR or non-MSI-H types—commonly referred to as “cold tumors”—which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) “hot tumors” typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China, Japan, and the top five European markets (UK, France, Germany, Spain, and Italy), representing a potential market size of USD $9 billion.

Anbogen stated that the FDA’s IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need.

Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion.

About Anbogen Therapeutics

Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets:

ABT-301, a HDAC1/2/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs.

ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications.

For more information, please visit Anbogen’s official website at www.anbogen.com.

Open for Business: Samsung Electronics Singapore Unveils Business Experience Studio

State-of-the-art studio designed to help customers envision how cutting-edge technology from Samsung can help address next wave digitisation


SINGAPORE – Media OutReach Newswire – 4 August 2025 – Samsung Electronics Singapore has unveiled its new Business Experience Studio, designed to help businesses unlock the potential of innovative technology solutions from Samsung. The 2,150 square feet studio is designed to help customers envision how they can adopt cutting-edge Samsung solutions to address their specific verticals and business digitalisation needs.

Timothy Tan, Head of Integrated Business, Samsung Electronics Singapore and Jeffrey Hahn, President, Samsung Electronics Singapore at the Business Experience Studio
Timothy Tan, Head of Integrated Business, Samsung Electronics Singapore and Jeffrey Hahn, President, Samsung Electronics Singapore at the Business Experience Studio

The studio houses builtfor-business solutions from Samsung, including its professional display range, enterprise-ready Galaxy devices, as well as business solutions such as Samsung Knox, Samsung VXT and SmartThings Pro. It also features a wide variety of solutions, designed with various local solutions partners, for specific business and vertical use cases built on Samsung’s hardware and platforms.

“Business rules are being rewritten today as companies need to be agile to respond to a fast-moving market that is highly influenced by evolving market conditions and technology advancements. The Business Experience Studio aims to demonstrate and inspire our customers on how they can design and deploy purposeful solutions from Samsung within their organisations,” said Timothy Tan, Head of Integrated Business, Samsung Electronics Singapore.

Helping Singapore businesses ride the next wave of digitisation

Today, more than nine in ten businesses in Singapore are operating with some level of digitalisation, but not all of them are unlocking optimal value from their technology investments.

The Business Experience Studio serves to demonstrate the breadth and depth of Samsung’s solutions for different verticals and business needs, and how it can unlock the value of a right technology partner for organisations.

Command and Control Centre features high-resolution commercial displays, integrated with Samsung’s VXT and SmartThings Pro solutions to help organisations achieve workflow optimisation and efficient energy management
Command and Control Centre features high-resolution commercial displays, integrated with Samsung’s VXT and SmartThings Pro solutions to help organisations achieve workflow optimisation and efficient energy management

The studio showcases an integrated deployment of Samsung hardware and solutions across ten different zones. It is powered by Samsung’s suite of business solutions, including Samsung Visual eXperience Transformation (VXT), SmartThings Pro, and Samsung Knox. Together, these proprietary business solutions from Samsung enable seamless integration and management of devices, solutions and services across enterprise environments. For example:

  • Samsung Visual eXperience Transformation (VXT) is a cloud-based digital signage solution that enables seamless content creation and management across all Samsung displays.
  • SmartThings Pro offers organisations a comprehensive platform to help in automation and monitoring through its intuitive dashboard facilitating effective device management, optimised for operations across residential, commercial, and public spaces such as schools. Visitors can monitor the status of smart connected devices with the studio including brand’s HVAC solutions, consumer and commercial displays.
  • Cybersecurity is a business-critical issue that calls for integration across all functions and levels within an organisation. At Samsung, security is always top-of-mind, and never an afterthought. Samsung Knox is the brand’s commitment in delivering a security platform that works in real-time to protect and defend connected devices against evolving digital threats.

The studio also features the use of Samsung’s products for specific verticals and business scenarios:

  • Creating immersive guest experiences with highly customisable commercial displays, including The Wall, digital and LED signages, and commercials TVs. For example, LED screens that can be configured into curved, L-shaped and for ceiling installation that are commonly seen in mixed-use developments, malls, and more.
  • Custom solutions for hospitality and healthcare sectors, where Samsung display and mobile solutions can be personalised to enhance end-customer experience from point of stay to departure. Galaxy wearables are also introduced as step-down care solutions, to offer more holistic after-care experiences.
  • Transforming retail with Samsung and partner solutions aimed at improving operational efficiencies and staff productivity, including Samsung Kiosk, Colour E-Paper EMDX, Knox Capture and other partner solutions.
  • Improved frontline communication and workflow with Samsung Rugged devices that are built to withstand harsh outdoor environments with IP68 & MIL-STD-810H ratings. With push-to-talk (PTT) capabilities on these rugged devices, end-users can stay connected and continue their workflows without interruption, even when they face unexpected incidents, or are operating in unpredictable environments
  • Smart classrooms where educators can better engage learners using managed and interactive solutions via 5K UHD supersized displays, E-Boards, Galaxy Tablets and Knox suite of solutions. In addition, the team also conducts workshops for local educators and students to introduce generative AI skills, including Galaxy AI features, to equip customers with relevant AI know-how.
  • Command and Control Centre setup, powered by Samsung’s business solutions and high-resolution business displays and the seamless video wall with narrow bezel measuring just 0.44 mm to enhance the overall productivity and decision-making abilities of backend teams.

The Business Experience Studio also showcases hardware solutions from Samsung designed to improve staff productivity and efficiencies, as well as to enhance overall guest experiences
The Business Experience Studio also showcases hardware solutions from Samsung designed to improve staff productivity and efficiencies, as well as to enhance overall guest experiences

Customers visiting the studio can also see a wide ecosystem of partner solutions in action, designed to demonstrate how Samsung’s solutions can be personalised and customised for specific business needs. For example, a “Tap on Glass” contactless payment solution on a Galaxy tablet shows how the payment journey can be automated while eliminating the use of a separate POS or card terminals, hence improving operational efficiencies.

The Business Experience Studio will complement the efforts of Samsung Singapore’s Integrated Business Team, comprising over 20 sectoral leads, solution architects and consultants, who will work closely with customers to deliver innovative, relevant and practical solutions for their business operations.

A multi-disciplinary team with deep B2B, consumer and vertical experience, the group will work closely with public and private sector customers and partners to design and deploy Samsung and partner solutions aimed at transforming user and employee experiences, as well as improving overall efficiencies and business outputs. As a leading technology and OEM partner with a vast product portfolio, Samsung will offer end-to-end support to address customers’ evolving business needs with its innovative and sustainable product and partner ecosystem.

“The Integrated Business Team and Business Experience Studio will demonstrate to customers our innovative and openness approach. We want to be able to facilitate meaningful collaboration that will ultimately deliver impactful business outcomes,” added Mr Tan.

The Business Experience Studio is open for bookings via https://www.samsung.com/sg/business.

Hashtag: #SamsungElectronicsSingapore





The issuer is solely responsible for the content of this announcement.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, digital signage, smartphones, wearables, tablets, home appliances and network systems, as well as memory, system LSI and foundry. Samsung is also advancing medical imaging technologies, HVAC solutions and robotics, while creating innovative automotive and audio products through Harman. With its SmartThings ecosystem, open collaboration with partners, and integration of AI across its portfolio, Samsung delivers a seamless and intelligent connected experience. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 4, 2025 /PRNewswire/ — Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, a leading ophthalmic research institution in China.

Unmet Needs in DED Management

Dry eye is a multifactorial ocular surface disease. Management of DED is often complex. The challenge to develop management and treatment strategies that are not overly complicated for our patients. Current clinical approaches include physical interventions and pharmacological therapies. For patients with moderate-to-severe DED, treatment typically requires combination therapies. Many patients rely on two to three topical ophthalmic agents administered multiple times daily, a regimen that often leads to poor patient compliance due to its complexity. It may result in incomplete treatment courses, perpetuating a “remission-relapse vicious cycle”. Breaking this cycle demands therapies that provide symptomatic relief and address underlying pathophysiology, coupled with patient-centric treatment modalities to improve patient compliance.

About RTP-008

RTP-008, developed based on Raytone’s iSus® bioabsorbable sustained-release drug delivery platform, is a novel ophthalmic therapeutic designed to address the complexities of dry eye disease. The dual mechanism of action of RTP-008 addresses two key pathological aspects, including tear retention and anti-inflammatory.

Professor Ying Jie and Professor Lei Tian, Principal Investigators of the trial, commented,” The favorable tolerability observed in the first patient is an encouraging signal. We will closely monitor the patients and look forward to demonstrating robust clinical efficacy.”

Dr. Yanbo Ling, CEO of Raytone, stated, “This milestone marks our transition from preclinical development to clinical trials, opening new possibilities for patients with moderate-to-severe dry eye. Raytone will also research and develop other ocular drug-device combination products in parallel, while extending its mature products into the field of pet healthcare.”

About Raytone Biotech

Raytone Biotech is an innovative biotech company specializing in ocular bioabsorbable sustained-release technologies, dedicated to addressing clinical challenges associated with traditional eye drops. The company’s iSus® technology platform enables precise drug release that lasts from days to months following a single administration. Raytone is dedicated to driving the transformation of ophthalmic treatment towards a “long-lasting and precise” model, bringing benefits to people with eye diseases worldwide.

86-572-2600633
info@raytonebio.com 

OCI Confirms Q3 2025 USD 700 Million Extraordinary Cash Distribution

AMSTERDAM, Aug. 4, 2025 /PRNewswire/ — OCI Global (Euronext: OCI), (“OCI,” the “Company”) announces today that it will pay a USD 700 million distribution (USD 3.31 per share) on 5 September 2025 through a mix of capital repayment and extraordinary cash dividend. This distribution is pursuant to the resolutions adopted at OCI’s annual general meeting on 21 May and will follow the lapsing of the mandatory creditor opposition period on 13 August. The ex-dividend date is 18 August, and the record date is 19 August.

Of the USD 700 million distribution, a proportion will be made as a repayment of capital corresponding to the amount of OCI’s remaining fiscal reserve, to be determined using the appropriate exchange rate on 3 September. Shareholders that do not wish to receive a capital repayment can elect to receive an extraordinary cash dividend from the profit reserve instead. Shareholders that do not make a choice will participate in a portion of their distribution paid as a repayment of capital. The Company will make distributions in USD unless the relevant shareholder has opted for a distribution in EUR. The EUR equivalent amount for those shareholders that elect for payment in EUR will be determined using the appropriate exchange rate on 3 September. The shareholder election period will run from 20 August through 2 September.

This press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

About OCI Global
Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

HONG KONG, Aug. 4, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). The trial will evaluate cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab. Akeso is now moving forward with the initiation of the study.

The COMPASSION-36/AK104-225 study is a key part of cadonilimab’s global development for hepatocellular carcinoma, continuing Akeso’s mission to advance cancer immunotherapy standards and to address the current limited survival benefits of single-target therapies.  This international, multicenter Phase II trial is designed to tackle the common issue of limited treatment options following resistance to immune checkpoint inhibitors (IO) in cancer therapy.

Currently, immune checkpoint inhibitor (IO) combination therapies have become the standard first-line treatment for various advanced malignancies. However, for patients worldwide whose disease progresses after IO combination therapy, there is a lack of effective second-line treatment options. The very limited second-line treatment options for advanced malignancies drives the critical need to explore new therapeutic strategies. Cadonilimab-based combination therapies have shown substantial potential in overcoming IO resistance across multiple tumor types.

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with approximately 865,000 new cases of liver cancer reported globally in 2022. The combination of atezolizumab and bevacizumab (A+T regimen) is the standard first-line therapy for advanced HCC, as recommended by the NCCN guidelines. However, for patients whose disease progresses after first-line A+T treatment, there is currently no FDA-approved second-line therapy available in the U.S., and also no approved treatment options from the NMPA in China. This creates a significant unmet need in the clinical management of these patients.

Cadonilimab is the first bispecific antibody for cancer immunotherapy to be approved globally and also the first bispecific antibody to be approved in China. The potential of cadonilimab for the treatment of HCC has been validated in multiple studies:

  • At the 2023 European Society for Medical Oncology Asia Congress (ESMO Asia), a study was presented demonstrating that cadonilimab, combined with FOLFOX-HAIC as neoadjuvant therapy, achieved a 100% disease control rate (DCR) in patients with resectable multinodular HCC, with an acceptable safety profile.
  • Additionally, data presented at the 2023 European Society for Medical Oncology (ESMO) Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC shows superior antitumor activity compared to currently approved therapies for advanced HCC.

Akeso’s exploration of combination therapies with cadonilimab in the treatment of HCC offers a broad and effective approach to disease management. These combinations address both early and advanced stages of HCC and provide promising therapeutic options for a wide range of patients:

  • In addition to the international multicenter Phase II registrational study COMPASSION-36, patient enrollment for the Phase III clinical trial of cadonilimab as adjuvant therapy for high-risk recurrence following curative surgery for HCC has been completed.
  • Furthermore, a Phase III registrational study of cadonilimab combined with lenvatinib and transarterial chemoembolization (TACE) for the treatment of intermediate to advanced unresectable HCC is currently ongoing.
  • Additionally, multiple Phase II studies investigating cadonilimab in combination with pulocimab (VEGFR-2), ivonescimab (PD-1/VEGF), and other therapies are currently underway for PD-1/L1 inhibitor-resistant non-small cell lung cancer (NSCLC), HCC, and other malignancies. These studies demonstrate cadonilimab’s potential in treating IO-resistant tumors.

Dr. Yu Xia, Founder, Chairwoman, President, and CEO of Akeso, remarked, “We are excited to initiate cadonilimab’s first international multicenter registrational trial, a pivotal step in addressing the global challenge of cancer immunotherapy resistance. This study represents a key milestone in Akeso’s global strategy to address the substantial clinical unmet needs in oncology. Akeso is advancing the clinical development of its innovative pipeline, including ivonescimab, cadonilimab, ligufalimab (CD47), and AK146D1 (Trop2/Nectin4 bispecific ADC) through both in-house initiatives and strategic global collaborations. Our goal is to provide accessible and impactful survival benefits to patients worldwide, and to position Akeso at the forefront of oncology innovation.”

Forward-Looking Statement of Akeso, Inc.

This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.